Cihan Ay, MD (he/him/his)

Professor, Head of the Thrombosis and Haemostasis Research Group
Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria
Vienna, Wien, Austria

Presentation(s):

• OC 02.4 - Women with severe postpartum hemorrhage have a decreased endogenous thrombin potential before delivery

  Saturday, June 24, 2023
  13:45 – 14:00 ET

• OC 12.3 - Rates of Venous Thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital Hemophilia A or B: a systematic review

  Sunday, June 25, 2023
  11:15 – 11:30 ET

• OC 21.1 - Venous thromboembolism and vascular access thrombosis in patients with end-stage kidney disease on hemodialysis: Prospective results from the VIVALDI study

  Sunday, June 25, 2023
  14:45 – 15:00 ET

• PB0031 - Natural antibodies to oxidation-specific epitopes characterize hemodialysis patients protected from cardiovascular events

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0411 - Platelet glycoprotein IIb- and IIIa levels are altered in persistently lupus anticoagulant positive patients with a history of thrombosis

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0462 - Early discharge and home treatment of patients with acute pulmonary embolism in the tertiary care setting

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• OC 34.3 - Walking capacity in patients with acute deep vein thrombosis is associated with the location of thrombosis and is reduced in patients with a history of previous deep vein thrombosis

  Monday, June 26, 2023
  11:15 – 11:30 ET

• OC 46.4 - Association of growth differentiation factor-15 (GDF-15) with thromboembolism and mortality in patients with cancer: findings from the Vienna CATS study

  Monday, June 26, 2023
  15:30 – 15:45 ET

• OC 46.5 - Tissue Factor Pathway Inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

  Monday, June 26, 2023
  15:45 – 16:00 ET

• PB0919 - High rates of bleeding in unselected patients with cancer: results from a prospective cohort study

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0926 - Venous thromboembolism and risk of depression in patients with hematological cancer: A population-based cohort study

  Monday, June 26, 2023
  18:30 – 19:30 ET

• OC 54.1 - Effectiveness and Safety of Rivaroxaban and Low Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism: A Meta-Analysis of OSCAR Programme Findings

  Tuesday, June 27, 2023
  10:45 – 11:00 ET

• OC 64.2 - Trends in clinical characteristics, treatment and 30-day outcomes in cancer patients with venous thromboembolism from 2001 to 2020

  Tuesday, June 27, 2023
  15:00 – 15:15 ET

• PB1206 - Plasmin generation is impaired in patients with bleeding disorders of unknown cause

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1277 - Thrombin generation and clot formation and lysis properties in hemophilia A with and without emicizumab

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1292 - Rationale and Design of pathfinderReal: A Prospective, Non-Interventional Study Assessing Joint Health in Adults With Haemophilia A After Switching to Prophylaxis With Turoctocog Alpha Pegol (N8-GP)

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1345 - Health-related quality of life assessed by the SF-36 Health Survey in the Vienna ITP Biobank

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1365 - Serum complement levels in adult patients with primary immune thrombocytopenia

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1511 - Systematic review on hemostatic biomarkers predictive for postpartum hemorrhage

  Tuesday, June 27, 2023
  18:30 – 19:30 ET

• PB1514 - Pre-delivery thrombin generation in women with non-severe post-partum hemorrhage – a nested case-control study

  Tuesday, June 27, 2023
  18:30 – 19:30 ET